Section 01
What it's used for
Mimicking exercise's metabolic effects
MOTS-c is being studied for reproducing effects of exercise: burning more fat, improving how the body responds to insulin, and boosting mitochondria, the cell's energy factories, as a possible approach for disease linked to inactivity.
▸Clinical wording
MOTS-c reproduces many metabolic effects of exercise: enhanced fat oxidation, improved insulin sensitivity, increased mitochondrial function. Research positions it as a potential treatment for sedentary-related metabolic disease.
Blood sugar effects in mice
In mice made obese by diet or naturally aged, MOTS-c restored the body's response to insulin, lowered fasting blood sugar, and improved glucose tolerance. These are animal findings; no study compared MOTS-c directly to exercise.
▸Clinical wording
Preclinical studies in diet-induced obesity and aged mouse models show MOTS-c restores insulin sensitivity, reduces fasting glucose, and improves glucose tolerance. These findings come from animal studies; no study comparing MOTS-c's effects directly to exercise intervention was found.
Aging and longevity in mice
MOTS-c levels naturally fall with age. In aged mice, giving MOTS-c improved physical performance, metabolic health, and healthspan, meaning years lived in good health, suggesting a possible anti-aging use that is still under study.
▸Clinical wording
MOTS-c levels decline with age. Supplementation in aged mice improves physical performance, metabolic health, and healthspan, suggesting potential anti-aging applications.
Preventing weight gain in animals
In animal models, MOTS-c prevented diet-induced obesity by increasing the body's energy use and fat burning, not by reducing how much the animals ate. This effect has been shown only in animals, not yet demonstrated in people.
▸Clinical wording
MOTS-c prevents diet-induced obesity in animal models through enhanced energy expenditure and fat oxidation, without reducing food intake.
Bone formation research
Recent research shows MOTS-c encourages bone-building cells called osteoblasts to mature and form new bone, working through a cell energy-sensing pathway called AMPK. This finding comes from research studies, not everyday clinical use.
▸Clinical wording
Recent research shows MOTS-c promotes osteoblast differentiation and bone formation through AMPK-dependent pathways.
Section 02
Mechanism of Action
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA. Its reported actions converge on the cellular energy sensor AMPK, but also include one direct protein binding partner and a move into the nucleus during metabolic stress. Most of the mechanistic data come from cultured cells and mice; human observations are limited to expression and cohort studies.
Vitamin pathway block wakes the energy sensor
- In human cells the peptide drained folate vitamin products and stalled the building of new DNA parts.
- A leftover intermediate piled up about twentyfold and mimics the cell's low-fuel signal.
- The cell's main energy sensor switched on, even though actual fuel levels were not low.
- Adding folic acid to the dish reversed the whole effect.
▸Clinical wording
Folate cycle blockade and AICAR-driven AMPK activation
In HEK293 cells stably expressing MOTS-c, metabolomics showed depletion of 5-methyl-tetrahydrofolate and methionine alongside elevated homocysteine, while de novo purine biosynthesis was blocked and its intermediate AICAR accumulated roughly 20-fold. AICAR is an AMP mimetic, and AMPKα (Thr172) and its substrate ACC (Ser79) were phosphorylated in a time- and dose-dependent manner — notably with AMP lower and ATP higher, so the trigger appears to be AICAR rather than a shifted AMP/ATP ratio. Adding folic acid (100 nM) reversed the phenotype in culture; the same folate-cycle targeting is shared with methotrexate.
Muscle takes up sugar faster
- Rat muscle cells making the peptide pulled sugar from the medium faster and burned it harder.
- Blocking the energy sensor cut that effect by roughly 40 percent, which points to the route.
- In mice, whole-body sugar handling improved while the liver's own sugar output stayed unchanged.
- A week of treatment brought sugar uptake in old mouse muscle back toward young levels.
▸Clinical wording
Skeletal muscle glucose handling downstream of AMPK
Skeletal muscle is described as the primary target tissue. L6 rat myotubes overexpressing MOTS-c cleared glucose from the medium faster and showed higher glycolytic capacity; blocking AMPK with compound C cut the glucose-stimulated glycolytic rate by about 40%, and AMPKα2 knockdown by 16%. In mice, hyperinsulinemic-euglycemic clamps gave roughly 30% higher glucose infusion rates with improved insulin-stimulated disposal while hepatic glucose production was unchanged; treated muscle showed AMPK activation and increased GLUT4 expression, and seven days of treatment restored 2-deoxyglucose uptake in soleus of old mice toward young levels.
A direct partner enzyme in muscle
- Binding experiments show the peptide sticks tightly to one enzyme and raises its activity.
- In immobilised mice it prevented muscle wasting and raised sugar uptake into muscle.
- Both effects disappeared when that enzyme was blocked or switched off.
- A natural human variant binds the enzyme sixteen times more weakly and does not reproduce the effects.
▸Clinical wording
Direct binding and activation of casein kinase 2
Surface plasmon resonance and dot-blot work identify CK2α as a direct binding partner of MOTS-c, with a dissociation constant near 1 nM, and MOTS-c raised CK2 activity toward its substrate in cell-free systems. In mice, systemic MOTS-c prevented immobilization-induced muscle atrophy and increased 2-deoxyglucose uptake into skeletal muscle; both effects were lost with the CK2 inhibitor CX-4945 or with CK2α knockdown. The action is tissue-specific — CK2 is stimulated in muscle but suppressed in fat. The naturally occurring K14Q variant (m.1382A>C) binds CK2α about 16-fold more weakly and does not reproduce these effects.
Moving into the nucleus under stress
- Starving cells of sugar or serum, or stressing them chemically, sends the peptide into the nucleus.
- That move needs the energy sensor and reverses on its own within a day.
- Inside, it binds control regions of antioxidant genes and partners with their master regulator.
- Sequencing found 802 genes whose activity changed under sugar restriction.
▸Clinical wording
Nuclear translocation and ARE-linked gene expression
In HEK293 and HepG2 cells, glucose restriction, serum deprivation and oxidative stress (tBHP) drive a transient move of MOTS-c into the nucleus that reverses within 24 hours. The step is AMPK-dependent: compound C and AMPKα siRNA block it, while metformin and AICAR trigger it within an hour. Once nuclear, MOTS-c binds antioxidant response element (ARE) sequences in promoters of NRF2 target genes such as HMOX1, NQO1, TXN and GPX2, and interacts with NFE2L2/NRF2 and ATF1; RNA-seq found 802 genes regulated under glucose restriction. Its hydrophobic core and cationic tail are required for DNA binding.
Exercise raises it, with conflicting human data
- In ten sedentary young men one cycling session raised muscle levels about twelvefold straight after exercise.
- The rise in blood was smaller and back to baseline within four hours.
- In mice, treatment improved running capacity at three different ages and made mitochondria work better.
- A separate human study found no release from the exercising leg, so the human data disagree.
▸Clinical wording
Exercise-responsive expression and mitochondrial bioenergetics
In ten sedentary young men, a cycling bout raised skeletal muscle MOTS-c about 11.9-fold immediately after exercise, with a smaller rise in plasma that returned to baseline within four hours; in mice, treatment shifted muscle transcriptomes toward AMPK signalling, glycolysis and proteostasis and improved running capacity at 2, 12 and 22 months of age. In two transgenic mouse strains, MOTS-c improved mitochondrial bioenergetic performance in a PGC-1α- and AMPK-dependent manner and lowered mitochondrial ROS emission without changing respiratory protein content. A separate human knee-extensor protocol found no arterio-venous MOTS-c difference across the exercising leg.
Section 03
Biological Pathways
- Folate-cycle blockade activates AMPKIn cultured cells MOTS-c depletes folate-cycle metabolites, accumulating the AMP-mimetic AICAR roughly 20-fold, which phosphorylates AMPK and its substrate ACC even as AMP itself stays lower.
- AMPK/GLUT4 glucose uptake in muscleIn myotubes and mouse muscle, AMPK activation raises GLUT4 and glucose disposal; blocking AMPK cuts the glycolytic response about 40%, and treatment restores old-mice glucose uptake toward young levels.
- Direct casein kinase 2 bindingMOTS-c binds CK2-alpha directly at nanomolar affinity and raises its activity; in mice this binding is required to prevent immobilization-induced muscle atrophy and to increase muscle glucose uptake.
- Nuclear translocation and ARE gene regulationUnder glucose restriction or oxidative stress, MOTS-c moves into the nucleus in an AMPK-dependent step and binds antioxidant response elements in NRF2 target promoters, regulating hundreds of genes.
- Exercise-responsive mitochondrial bioenergeticsA cycling bout raised skeletal muscle MOTS-c nearly 12-fold in young men, and in transgenic mice it improved mitochondrial bioenergetic performance and lowered ROS emission in a PGC-1-alpha-dependent manner.
Section 04
Dosage Information
MRWQEMGYIFYPRKLR| Route / system | Context | Range studied | Limitation |
|---|---|---|---|
| Subcutaneous — first human trial | Phase 2a in prediabetes with overweight or obesity | A fixed daily dose for 12 weeks, never named in the registry. 120 participants, recruiting since February 2026, finishing February 2027 | The first trial to give MOTS-c to people exists; its dose is not public and its data do not exist yet. Nothing on record supports any particular amount. |
| Into the belly (intraperitoneal) — mice | Mouse metabolic and exercise models | 0.5 mg/kg daily 8 weeks on a fatty diet, 5 mg/kg daily 7 days before a glucose test, one 15 mg/kg dose 10 min before a treadmill run | Injections into mice. The same mg/kg in a 70–90 kg adult is 35 mg to 1.35 g, and no scaling and no human study has ever bridged that gap. |
| Body's own level — measured, not given | Observational human studies; nothing was given to anyone | Blood levels of about 2–4 ng/mL in athletes and non-athletes, reference values of 45.9–218.5 ng/mL, and 835 ± 266 ng/mL elsewhere | This is what the body already holds, not a dose. Three test kits disagree by two orders of magnitude, so even the baseline an injection would aim at is unclear. |
| Subcutaneous — self-administration | Vendor protocols and community practice, outside any trial | 2.5–10 mg per injection, three times weekly up to daily, in 8–12 week cycles — about 28–143 µg/kg for a 70–90 kg adult | Circulating practice, not a finding. The widely repeated claim of a phase 1 safety study at up to 10 mg matches no entry in the ClinicalTrials.gov registry. |
Results
Syringe Fill Level (100u syringe)
Set positive values for: Recommended dose per kg.
Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.
Section 05
Protocols
- Protocol 01
Comprehensive Longevity Stack
Multi-peptide anti-aging protocol combining telomerase activation, mitochondrial support, and GH optimization.
- Focus
- Anti-Aging
- Level
- Advanced
- Duration
- 3–6 months
Section 06
Stability & Storage
Lyophilised powder
The lyophilised powder is kept at −20 °C for long-term stability. It is reconstituted with bacteriostatic water or sterile saline before use.
After reconstitution
Once reconstituted, the peptide is stored at 2–8 °C and used within 21 days. The solution is kept refrigerated between doses to preserve stability.
Section 07
Side Effects & Precautions
MOTS-c has limited human safety data, since research on it remains mostly preclinical.
What animal studies show
No significant toxicity has been found in animal studies.
Theoretical risk to cell energy balance
There is a theoretical risk that excessive activation of AMPK could affect cellular energy balance.
Interaction risk with diabetes medications
Combining MOTS-c with diabetes medications could potentially cause low blood sugar (hypoglycemia).
Section 08
Regulatory Status
The compound sits at a preclinical-to-early-translational stage: no completed interventional human trial exists for MOTS-c itself, while WADA already treats it as a prohibited performance-enhancing substance.
FDA / United States
Not approved, and not on the 503A list
No IND application or completed human trial supports MOTS-c, and it was not on the 503A Bulks List as of 5 August 2026 — section 503A therefore opens no lawful route for a pharmacy to compound it.
FDA review
A committee has recommended listing it
On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 7 to 5 to add MOTS-c to the 503A Bulks List; the vote does not bind the FDA, and the list changes only through formal rulemaking, not complete as of this check.
WADA
Prohibited under category S4.4
WADA names MOTS-c explicitly among AMPK-activator metabolic modulators in the 2026 Prohibited List, banning it in and out of competition even though no regulator has approved it as a medicine.
Clinical trials
No completed interventional trial exists
Human data come only from observational biomarker studies (NCT04027712) and from a modified analogue, CB4211; a placebo-controlled phase 2a study in prediabetes and obesity (NCT07505745) is registered but not yet reported.
Regulatory status differs between jurisdictions and changes over time — a committee recommendation is not an approval, and a WADA ban does not require one. Check the current documents of your own regulator and sport authority before relying on any of this.
We cover the 23–24 July 2026 vote of the FDA's Pharmacy Compounding Advisory Committee (PCAC) separately, in «The 2026 PCAC Peptide Vote» (/en/articles/fda-pcac-2026-peptides). In short: on 23 July the committee recommended adding MOTS-c to the 503A Bulks List — 7 votes to 5, against the written position of the FDA's own reviewers. The recommendation binds no one: the list changes only through formal rulemaking, which usually takes 8–12 months, and even a place on it would not make MOTS-c an approved medicine.
Section 09
Research Studies
- [1]The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistanceLee C, Zeng J, Drew BG, et al. · Cell Metabolism · 2015
- [2]The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stressKim KH, Son JM, Benayoun BA, Lee C · Cell Metabolism · 2018
- [3]MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasisReynolds JC, Lai RW, Woodhead JST, et al. · Nature Communications · 2021
- [4]MOTS-c modulates skeletal muscle function by directly binding and activating CK2Kumagai H, Kim SJ, Miller B, et al. · iScience · 2024
- [5]MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent mannerGudiksen A, Hansen CC, van der Stede T, et al. · Free Radical Biology and Medicine · 2026
Section 10
Frequently Asked Questions
Nearly all the supporting evidence - restored insulin sensitivity, increased fat oxidation, prevention of diet-induced obesity - comes from mouse studies. The first human trial (a phase 2a study in overweight or obese people with prediabetes, 120 participants) began recruiting in February 2026 and finishes in February 2027, and its dose has not been made public; no human efficacy data exist yet for any outcome.
Self-administration outside any trial runs 2.5-10 mg per injection, three times weekly up to daily, in 8-12 week cycles - about 28-143 µg/kg for a 70-90 kg adult. This is circulating practice, not a research finding: the mouse doses used experimentally (0.5-15 mg/kg) would translate to 35 mg-1.35 g in a human by simple weight scaling, and no study has bridged that gap or tested a human dose.
In mice, MOTS-c produced its metabolic effects - higher fat oxidation, better insulin sensitivity - through injection alone, which is what earns it the label "exercise mimetic" in the preclinical literature. Whether that holds in a person who isn't exercising has not been tested: the one human trial underway measures a fixed treatment against a prediabetes/obesity endpoint, not exercise-independence.
Human safety data are essentially absent because MOTS-c has never completed a human trial. Animal studies show no significant toxicity; the theoretical concerns raised are excessive AMPK activation disrupting cellular energy balance and hypoglycaemia if combined with diabetes medications, but neither has been observed in a person because no one has measured it.
MOTS-c is an investigational compound in preclinical and early translational research, not approved by any regulatory authority for any use. It is not currently on WADA's prohibited list, though that classification may change as human trials progress.
No study has tested MOTS-c alongside any of these compounds. The interaction and combination questions circulating online have no clinical or preclinical data behind them in MOTS-c's own research record.
The lyophilised powder is kept at -20 °C for long-term storage and reconstituted with bacteriostatic water or sterile saline. Once reconstituted, it is kept at 2-8 °C and used within 21 days.